O	0	6	Effect
O	7	9	of
B-intervention	10	22	Rosuvastatin
O	23	25	in
O	26	36	Preventing
B-condition	37	49	Chemotherapy
I-condition	49	50	-
I-condition	50	57	Induced
I-condition	58	72	Cardiotoxicity
O	73	75	in
O	76	81	Women
O	82	86	With
O	87	93	Breast
O	94	100	Cancer
O	100	101	:
O	102	103	A
O	104	114	Randomized
O	114	115	,
O	116	122	Single
O	122	123	-
O	123	128	Blind
O	128	129	,
O	130	137	Placebo
O	137	138	-
O	138	148	Controlled
O	149	154	Trial
O	154	155	.

O	156	168	Chemotherapy
O	168	169	-
O	169	176	induced
O	177	191	cardiotoxicity
O	192	194	is
O	195	196	a
O	197	202	major
O	203	206	and
O	207	214	leading
O	215	220	cause
O	221	223	of
O	224	229	death
O	230	232	in
O	233	239	breast
O	240	246	cancer
O	247	256	survivors
O	256	257	.

O	258	260	It
O	261	264	can
O	265	272	present
O	273	280	decades
O	281	286	after
O	287	299	chemotherapy
O	300	303	and
O	304	307	can
O	308	316	manifest
O	317	319	in
O	320	329	different
O	330	334	ways
O	334	335	;
O	336	340	some
O	341	357	chemotherapeutic
O	358	364	agents
O	365	369	have
O	370	371	a
O	372	380	powerful
O	381	385	dose
O	385	386	-
O	386	395	dependent
O	396	408	relationship
O	409	413	with
O	414	428	cardiotoxicity
O	428	429	.

O	430	433	The
O	434	437	aim
O	438	440	of
O	441	445	this
O	446	451	study
O	452	455	was
O	456	458	to
O	459	470	investigate
O	471	474	the
O	475	481	effect
O	482	484	of
O	485	497	rosuvastatin
O	498	500	on
O	501	511	preventing
O	512	524	chemotherapy
O	524	525	-
O	525	532	induced
O	533	547	cardiotoxicity
O	548	550	in
O	551	559	patients
O	560	564	with
O	565	571	breast
O	572	578	cancer
O	578	579	.

O	580	583	Our
O	584	589	study
O	590	593	was
O	594	595	a
O	596	606	randomized
O	606	607	,
O	608	614	single
O	614	615	-
O	615	620	blind
O	620	621	,
O	622	629	placebo
O	629	630	-
O	630	640	controlled
O	641	646	trial
O	647	651	that
O	652	660	involved
B-total-participants	661	663	89
B-eligibility	664	669	women
I-eligibility	670	674	with
I-eligibility	675	680	newly
I-eligibility	681	690	diagnosed
I-eligibility	691	697	breast
I-eligibility	698	704	cancer
I-eligibility	705	708	who
I-eligibility	709	713	were
I-eligibility	714	723	scheduled
I-eligibility	724	726	to
I-eligibility	727	734	receive
I-eligibility	735	747	chemotherapy
O	747	748	.

O	749	757	Patients
O	758	762	were
O	763	771	randomly
O	772	780	assigned
O	781	783	to
O	784	791	receive
O	792	804	rosuvastatin
O	805	807	or
O	808	809	a
B-control	810	817	placebo
O	818	820	in
O	821	822	a
O	823	824	1
O	824	825	:
O	825	826	1
O	827	832	ratio
O	833	836	for
O	837	838	6
O	839	845	months
O	845	846	.

O	847	863	Echocardiography
O	863	864	,
O	865	870	using
O	871	872	2
O	872	873	-
O	873	884	dimensional
O	885	886	(
O	886	888	2D
O	888	889	)
O	890	897	Doppler
O	897	898	,
O	899	905	tissue
O	906	913	Doppler
O	913	914	,
O	915	918	and
O	919	926	speckle
O	926	927	-
O	927	935	tracking
O	936	943	methods
O	943	944	,
O	945	948	was
O	949	953	used
O	954	956	to
O	957	966	determine
O	967	970	the
O	971	979	absolute
O	980	987	changes
O	988	990	in
O	991	994	the
O	995	999	left
O	1000	1011	ventricular
O	1012	1020	systolic
O	1021	1029	ejection
O	1030	1038	fraction
O	1039	1040	(
O	1040	1044	LVEF
O	1044	1045	)
O	1045	1046	,
O	1047	1051	left
O	1052	1063	ventricular
O	1064	1067	end
O	1067	1068	-
O	1068	1077	diastolic
O	1078	1084	volume
O	1085	1086	(
O	1086	1091	LVEDV
O	1091	1092	)
O	1092	1093	,
O	1094	1098	left
O	1099	1110	ventricular
O	1111	1114	end
O	1114	1115	-
O	1115	1123	systolic
O	1124	1130	volume
O	1131	1132	(
O	1132	1137	LVESV
O	1137	1138	)
O	1138	1139	,
O	1140	1144	left
O	1145	1151	atrial
O	1152	1153	(
O	1153	1155	LA
O	1155	1156	)
O	1157	1165	diameter
O	1165	1166	,
O	1167	1178	transmitral
O	1179	1186	Doppler
O	1187	1192	early
O	1193	1202	diastolic
O	1203	1211	velocity
O	1212	1213	(
O	1213	1214	E
O	1215	1219	wave
O	1219	1220	)
O	1220	1221	,
O	1222	1228	tissue
O	1229	1236	Doppler
O	1237	1242	early
O	1243	1252	diastolic
O	1253	1254	(
O	1254	1255	e
O	1255	1256	'
O	1256	1257	)
O	1258	1261	and
O	1262	1266	peak
O	1267	1275	systolic
O	1276	1277	(
O	1277	1278	s
O	1278	1279	'
O	1279	1280	)
O	1281	1287	mitral
O	1288	1295	annular
O	1296	1306	velocities
O	1306	1307	,
O	1308	1309	E
O	1309	1310	/
O	1310	1311	e
O	1311	1312	'
O	1313	1318	ratio
O	1318	1319	,
O	1320	1323	and
O	1324	1330	global
O	1331	1343	longitudinal
O	1344	1352	systolic
O	1353	1359	strain
O	1359	1360	.

O	1361	1364	The
B-outcome	1365	1369	LVEF
O	1370	1373	was
O	1374	1387	significantly
O	1388	1395	reduced
O	1396	1398	in
O	1399	1402	the
O	1403	1410	placebo
O	1411	1416	group
O	1417	1419	at
O	1420	1423	the
O	1424	1427	end
O	1428	1430	of
O	1431	1434	the
O	1435	1440	study
O	1441	1445	when
O	1446	1454	compared
O	1455	1459	with
O	1460	1463	the
O	1464	1472	baseline
O	1473	1478	value
O	1478	1479	.

O	1480	1487	However
O	1487	1488	,
O	1489	1494	there
O	1495	1498	was
O	1499	1501	no
O	1502	1513	significant
O	1514	1524	difference
O	1525	1527	in
O	1528	1531	the
B-outcome	1532	1536	LVEF
O	1537	1539	in
O	1540	1543	the
O	1544	1556	intervention
O	1557	1562	group
O	1563	1564	(
O	1564	1574	intergroup
O	1575	1576	P
O	1577	1578	=
O	1579	1580	.
O	1580	1583	012
O	1583	1584	)
O	1584	1585	.

O	1586	1597	Furthermore
O	1597	1598	,
O	1599	1607	compared
O	1608	1612	with
O	1613	1616	the
O	1617	1629	intervention
O	1630	1635	group
O	1636	1638	at
O	1639	1642	the
O	1643	1646	end
O	1647	1649	of
O	1650	1653	the
O	1654	1659	study
O	1659	1660	,
O	1661	1666	there
O	1667	1670	was
O	1671	1672	a
O	1673	1684	significant
O	1685	1693	increase
O	1694	1696	in
O	1697	1700	the
B-outcome	1701	1702	4
I-outcome	1702	1703	-
I-outcome	1704	1707	and
I-outcome	1708	1709	2
I-outcome	1709	1710	-
I-outcome	1710	1717	chamber
I-outcome	1718	1723	LVESV
I-outcome	1723	1724	,
I-outcome	1725	1727	LA
I-outcome	1728	1736	diameter
I-outcome	1736	1737	,
I-outcome	1738	1741	and
I-outcome	1742	1743	E
I-outcome	1743	1744	/
I-outcome	1744	1745	e
I-outcome	1745	1746	'
I-outcome	1747	1752	ratio
O	1753	1755	in
O	1756	1759	the
O	1760	1767	placebo
O	1768	1773	group
O	1774	1775	(
O	1775	1785	intergroup
O	1786	1787	P
O	1788	1789	=
O	1790	1791	.
O	1791	1794	019
O	1794	1795	,
O	1796	1797	P
O	1798	1799	=
O	1800	1801	.
O	1801	1804	024
O	1804	1805	,
O	1806	1807	P
O	1808	1809	<
O	1810	1811	.
O	1811	1814	001
O	1814	1815	,
O	1816	1819	and
O	1820	1821	P
O	1822	1823	=
O	1824	1825	.
O	1825	1828	021
O	1828	1829	,
O	1830	1842	respectively
O	1842	1843	)
O	1844	1847	and
O	1848	1849	a
O	1850	1861	significant
O	1862	1870	decrease
O	1871	1873	in
O	1874	1877	the
B-outcome	1878	1879	e
I-outcome	1879	1880	'
I-outcome	1881	1884	and
I-outcome	1885	1886	s
I-outcome	1886	1887	'
I-outcome	1888	1898	velocities
O	1899	1901	in
O	1902	1905	the
O	1906	1913	placebo
O	1914	1919	group
O	1920	1921	(
O	1921	1931	intergroup
O	1932	1933	P
O	1934	1935	<
O	1936	1937	.
O	1937	1940	001
O	1941	1944	and
O	1945	1946	P
O	1947	1948	<
O	1949	1950	.
O	1950	1953	006
O	1953	1954	,
O	1955	1967	respectively
O	1967	1968	)
O	1968	1969	.

O	1970	1973	The
O	1974	1981	present
O	1982	1987	study
O	1988	1994	showed
O	1995	1999	that
O	2000	2003	the
O	2004	2016	prophylactic
O	2017	2020	use
O	2021	2023	of
O	2024	2036	rosuvastatin
O	2037	2040	may
O	2041	2048	prevent
O	2049	2052	the
O	2053	2064	development
O	2065	2067	of
O	2068	2080	chemotherapy
O	2080	2081	-
O	2081	2088	induced
O	2089	2103	cardiotoxicity
O	2103	2104	.
